Education
About Us
Working with TipRanks
Follow Us
Statera BioPharma (STAB)
OTHER OTC:STAB
STAB Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
Volume2.50K
Average Volume (3M)N/A
Market Cap
$7.14K
Enterprise Value$14.42M
Total Cash (Recent Filing)$506.10K
Total Debt (Recent Filing)$7.41M
Price to Earnings (P/E)―
Beta11632.18
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding71,416,040
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap2.02K
Enterprise Value/Revenue1.32
Enterprise Value/Gross Profit5.57
Enterprise Value/Ebitda-0.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
STAB FAQ
What was Statera BioPharma’s price range in the past 12 months?
Currently, no data Available
What is Statera BioPharma’s market cap?
Statera BioPharma’s market cap is $7.14K.
When is Statera BioPharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Statera BioPharma’s earnings last quarter?
Currently, no data Available
Is Statera BioPharma overvalued?
According to Wall Street analysts Statera BioPharma’s price is currently Overvalued.
Does Statera BioPharma pay dividends?
Statera BioPharma does not currently pay dividends.
What is Statera BioPharma’s EPS estimate?
Statera BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Statera BioPharma have?
Statera BioPharma has 71,416,040 shares outstanding.
What happened to Statera BioPharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Statera BioPharma?
Currently, no hedge funds are holding shares in STAB
Company Description
Statera BioPharma
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.
Biodexa Pharmaceuticals
―
Salarius Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Onconetix
―